Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Morpheus-Gastric and Esophageal Cancer
2016-004529-17Phase 2Unknown
- Sponsor
- Roche
- Start
- Feb 2018
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of atezolizumab in gastric cancer (GC), esophagogastric junction cancer and esophageal cancer (8 arms), sponsored by Roche. Primary endpoint: Objective response rate. Status: unknown.
02
Drugs
atezolizumab
03
Conditions
gastric cancer (GC)esophagogastric junction canceresophageal cancer
Beyond the preview
Go deeper on 2016-004529-17.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2016-004529-17.